Spotlight: Celltrion's Remicade biosim kneecapped Merck in Europe

The FDA has officially green-lighted the Remicade biosimilar Inflectra, a med from South Korea's Celltrion and Pfizer's ($PFE) Hospira. But will the knockoff be able to capture the same kind of market share from Johnson & Johnson ($JNJ) that it's been stealing in Europe from Merck & Co. ($MRK)? Depends who you ask. More from FiercePharma

> Johnson & Johnson ($JNJ) inked a $85 million deal to develop and sell Tesaro's experimental prostate cancer pill niraparib. Report

> Amphastar Pharmaceuticals ($AMPH), which has come in for criticism for the price of its overdose antidote naloxone, agreed to give Connecticut a $6 rebate for each dose purchased by a state or municipal agency. Report

Webinar

Using AI and RWD to Uncover Rare Disease Insights, Accelerate Commercialization and Improve Patient Outcomes

Wednesday, March 24 | 2pm ET / 11am PT

Learn how IPM.ai transformed real world data into real world insights to assist Audentes in their development of AT132 for the treatment of XLMTM. The session reviews how IPM.ia and Audentes collaborated to uncover the XLMTM patient population.

> The cost of insulin treatments for diabetes rose by nearly 200% from 2002 to 2013, the Journal of the American Medical Association reports, as expensive new analog treatments supplanted older human insulins. Report

> Shire ($SHPG) released top-line Phase III data on its ADHD drug candidate SHP465 showing that the drug met its primary goal for improving symptoms in children and adolescents. Report

> Hedge funder Bill Ackman is set to explain a 25% quarterly loss to his investors Wednesday, with his bad bet on Valeant Pharmaceuticals ($VRX) first in line. Report

And Finally... Worldwide diabetes cases hit 422 million as the disease mushrooms in the developing world. Report